Israel - English - Ministry of Health

j-c health care ltd - erythropoietin human recombinant - solution for injection - erythropoietin human recombinant 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) orb: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgeries known be associated with excessive blood loss (at least 2 units ).

Israel - English - Ministry of Health

j-c health care ltd - recombinant human erythropoietin - solution for injection - recombinant human erythropoietin 3000 iu / 0.3 ml - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).

United States - English - NLM (National Library of Medicine)

vetdc, inc. - rabacfosadine succinate (unii: 3l28lg748i) (rabacfosadine - unii:m39bo43j9w) - rabacfosadine 16.4 mg - tanovea-ca1 is indicated for the treatment of lymphoma in dogs. do not use in dogs with pulmonary fibrosis or a history of chronic pulmonary disease that could lead to fibrosis, such as chronic bronchitis (see warnings). do not use in west highland white terriers due to a genetic predisposition for development of pulmonary fibrosis. use with caution in other terrier breeds due to potential genetic predisposition for development of pulmonary fibrosis. do not use in dogs that are pregnant, lactating, or intended for breeding. rabacfosadine is cytotoxic and can cause birth defects and affect female and male fertility. tanovea-ca1 has not been evaluated in pregnant, lactating, or breeding dogs.

United States - English - NLM (National Library of Medicine)

elanco us inc. - bexagliflozin (unii: ey00jf42fv) (bexagliflozin - unii:ey00jf42fv) - bexacat (bexagliflozin tablets) are flavored pentagonal, 10 mm, speckled white, brown, or tan biconvex with a characteristic odor. the empirical formula is c24h29clo7 and the molecular weight is 464.94 g/mol. the chemical name is (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol. the chemical structure of bexagliflozin is:

United States - English - NLM (National Library of Medicine)

elanco us inc. - rabacfosadine succinate (unii: 3l28lg748i) (rabacfosadine - unii:m39bo43j9w) - do not use in dogs with pulmonary fibrosis or a history of chronic pulmonary disease that could lead to fibrosis, such as chronic bronchitis (see warnings). do not use in west highland white terriers due to a genetic predisposition for development of pulmonary fibrosis. use with caution in other terrier breeds due to potential genetic predisposition for development of pulmonary fibrosis. do not use in dogs that are pregnant, lactating, or intended for breeding. rabacfosadine is cytotoxic and may cause birth defects and affect female and male fertility. tanovea has not been evaluated in pregnant, lactating, or breeding dogs.

Malta - English - Medicines Authority

bayer public limited company 400 south oak way, reading berkshire rg2 6ad, united kingdom - ciprofloxacin - solution for infusion - ciprofloxacin 2 mg/ml - antibacterials for systemic use

Malta - English - Medicines Authority

bayer public limited company - ciprofloxacin - tablet - ciprofloxacin 250 milligram(s) - antibacterials for systemic use

Malta - English - Medicines Authority

bayer public limited company - ciprofloxacin - tablet - ciprofloxacin 500 milligram(s) - antibacterials for systemic use

Malta - English - Medicines Authority

bayer public limited company - ciprofloxacin - solution for infusion - ciprofloxacin 200 milligram(s) - antibacterials for systemic use

Malta - English - Medicines Authority

bayer public limited company 400 south oak way, reading berkshire rg2 6ad, united kingdom - ciprofloxacin - solution for infusion - ciprofloxacin 400 mg - antibacterials for systemic use